More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura

Detalles Bibliográficos
Autores principales: Picod, Adrien, Benhamou, Ygal, Bouzid, Raïda, Veyradier, Agnès, Coppo, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333732/
https://www.ncbi.nlm.nih.gov/pubmed/36260763
http://dx.doi.org/10.1182/bloodadvances.2022009021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333732/
https://www.ncbi.nlm.nih.gov/pubmed/36260763
http://dx.doi.org/10.1182/bloodadvances.2022009021

Ejemplares similares